Triple Marker Test

Overview

The Triple Marker Test (also called the triple screen) is a prenatal blood screening performed between 14 and 18 weeks of pregnancy to estimate the risk that a fetus may have certain chromosomal abnormalities or neural tube defects. The test measures three maternal serum markers — Alpha-fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Unconjugated Estriol (uE3) — and combines those values with maternal information (age, weight, ethnicity, gestational age and ultrasound dating) to calculate a risk score. The Triple Marker Test is a non-invasive screening tool (about 70% sensitivity with ≈5% false positive rate) that helps clinicians decide whether to offer diagnostic testing such as amniocentesis or further imaging.

Symptoms

The Triple Marker Test itself produces no symptoms — it is a simple blood draw. Clinically, the test is ordered when there is concern about fetal development or when routine prenatal care calls for screening. A high-risk result from the Triple Marker Test alerts parents and doctors to look for possible signs of fetal problems on ultrasound or on further diagnostic tests. Typical concerns that follow a high-risk result include findings on the anomaly scan, abnormal fetal anatomy, or biochemical patterns suggesting:

1. Possible Down’s syndrome (Trisomy 21) — biochemical pattern: AFP ↓, uE3 ↓, hCG ↑.
2. Possible Edwards syndrome (Trisomy 18) — biochemical pattern: AFP ↓, uE3 ↓, hCG ↓.
3. Possible neural tube defect (spina bifida, anencephaly) — biochemical pattern: AFP elevated.

Remember: the Triple Marker Test is a screening test, not a diagnosis; abnormal results prompt further testing, not immediate conclusions.

Causes

The Triple Marker Test detects abnormal marker levels in the mother’s blood that are produced by the fetus, fetal liver or placenta:

1. AFP (Alpha-fetoprotein) originates mainly from the fetal liver. Elevated maternal AFP can indicate open neural tube defects or multiple pregnancy; low AFP can be seen in some chromosomal conditions.
2. hCG (Human Chorionic Gonadotropin) is produced by the placenta; abnormal hCG may reflect chromosomal aneuploidy, twin pregnancy or other placental differences.
3. uE3 (Unconjugated Estriol) comes from fetal and placental steroid metabolism; low uE3 contributes to risk patterns seen in chromosomal abnormalities.
4. Calculated risk depends on how each marker compares to the population median for that gestational age (MoM — Multiple of Median) and must be interpreted with accurate gestational dating, ultrasound findings and maternal factors. Factors such as HCG injections, IVF donor dates, diabetes, or medications may alter marker levels and must be declared at testing.

Risk factors

Certain maternal or pregnancy factors increase the likelihood that screening is recommended or that results may be affected:

1. Advanced maternal age (≥35 years) increases baseline risk for chromosomal abnormalities and is a common indication for screening.
2. Family history of genetic disorders or previous pregnancy with chromosomal anomalies.
3. Diabetes, IVF conception (donor factors) and certain medications or injections that change hormone levels.
4. Inaccurate pregnancy dating — incorrect gestational age will change MoM calculations and may lead to misleading results.
5. Multiple pregnancy (twins, triplets) — multiple gestations alter marker profiles (for example, higher hCG) and require adjusted interpretation.
6. Incomplete ultrasound information — a high-quality anomaly scan and precise gestational age are essential to interpret biochemical results correctly.

Prevention

Prevention in the context of the Triple Marker Test focuses on optimizing test accuracy and appropriate follow-up to reduce unnecessary anxiety and missed diagnoses:

1. Timing: perform the test between 14–18 weeks gestation for valid results.
2. Accurate dating: ensure gestational age is confirmed by ultrasound (anomaly scan) and provide exact LMP and ultrasound dates when submitting the sample.
3. Full clinical information: include maternal date of birth, weight, ethnicity, history of prior pregnancies, diabetes status, IVF details or HCG therapy — all of these affect risk calculations and interpretation.
4. Proper sample handling: collect 3.0 mL blood, separate serum promptly and send the sample with required clinical details to the laboratory.
5. Patient counseling: explain that the Triple Marker Test is a screening tool only — a high-risk result prompts diagnostic testing (e.g., amniocentesis) and genetic counseling; a negative result does not guarantee a healthy baby.
6. Follow-up plan: if the screen suggests elevated risk, arrange targeted ultrasound, specialist review and, where indicated, invasive diagnostic testing and counseling to confirm or exclude fetal abnormalities.